Communication Toolkit for Product X

Prepared by RTI Health Solutions
Month ##, 201#
## Contents

<table>
<thead>
<tr>
<th>Section 1 - Introduction</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Key Objectives</td>
<td>4</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Section 2 - Executive Summary</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disease Problem and Unmet Need</td>
<td>6</td>
</tr>
<tr>
<td>Product Value</td>
<td>17</td>
</tr>
<tr>
<td>Payer Value Proposition</td>
<td>21</td>
</tr>
</tbody>
</table>
SECTION 1

Introduction
Key objectives

- Compelling and comprehensive modules with different top-line value messages and in-depth evidence to support communication with payer stakeholders on the existing unmet needs in Disease X and the potential value of Product X.
- Summary of payer-relevant background information on the disease and unmet needs to set the scene for Product X.
- Synthesis of the key evidence of Product X in Disease X to demonstrate to payers the value and position of Product X.
- Repository for pertinent information to be provided to payer stakeholders.
SECTION 2

Executive Summary
US Impact of HIV

- The Centers for Disease Control and Prevention (CDC) estimates that more than 1 million people are living with HIV in the US
- 20% of people living with HIV are unaware of their infection
Breast Cancer: The Disease and Its Burden

Most diagnosed breast cancers are invasive at time of diagnosis

- 1 in 8 women (13%) in the US will have breast cancer during their lifetime
- About 70% of all invasive breast cancers are positive for ER and/or PgR expression at the time of diagnosis
- 15-25% of all breast cancers are HER2 overexpressing
- Postmenopausal women are more likely to be HR+
- About 40% of diagnosed patients may develop MBC
- Treatment for MBC is palliative, and median life expectancy after recurrence is 24-30 months or less
- Mean per patient per month costs (2004 US$) attributable to breast cancer were $2,896

The power of knowledge.
The value of understanding.
The power of knowledge.
The value of understanding.

Header

• Text
Some explanation about this chart

- could be here
• Introductions of new antiretrovirals with better tolerability and strong antiretroviral activity have led to a reduction in the rates of virologic failure and an increase in the number of patients remaining on their first-ever regimen

• In the US:
  – 81% have never virologically failed
  – 53% are on their first-ever regimen
  – 28% have switched for tolerability, highlighting the need for more tolerable treatments

• Due to improvements in therapy, the number of patients in the salvage segment (virologically failed and on 4+ antiretrovirals) is extremely small and diminishing in size
Current Unmet Needs in HIV

- Despite remarkable improvements in HIV treatment and prevention, economic and social barriers that result in continued morbidity, mortality, and new HIV infections persist
- Antiretroviral therapy (ART) has dramatically reduced HIV-associated morbidity and mortality and has transformed HIV into a chronic, manageable condition

Poor Adherence

- Adherence to HIV treatments remains suboptimal among both commercially insured and Medicaid HIV patients
  - 59% of commercially insured patients achieved ≥ 80% adherence, compared with 42% of Medicaid patients
  - Among commercially insured and Medicaid patients, treatment-experienced patients were more likely to be adherent than treatment-naïve patients
• Poor adherence may be attributable to tolerability issues
  – High switch rates
  – High discontinuation
• High adherence is required to prevent failure of virologic suppression, development of drug resistance, and permanent loss of therapeutic options
• In a study by Maggiolo et al., a the risk of virologic failure was:
  – 2.4% in patients with cART adherence of > 95%
  – 4.3% in patients with adherence rates of 86%-95%
  – 12.2% in patients with adherence rates of 76%-85%
  – 17.4% in patients with adherence rates of ≤ 75%
• World Health Organization (WHO) guidelines b state that adherence of at least 95% is desirable over long periods of time

---

cART = combination antiretroviral therapy; NNRTI = nonnucleoside reverse-transcriptase inhibitor; PI = protease inhibitor.

a Maggiolo et al. Clin Infect Dis. 2005 Jan 1;40(1):158-63. Note: Study was conducted in Italy.
• ART adherence among commercially insured and Medicaid HIV patients in the US is associated with improved economic outcomes
  – 29% and 31% reductions, respectively, in nonpharmacy costs ($P < 0.0001$)
  – 43% and 49% reductions, respectively, in hospitalizations ($P < 0.0001$)
  – 41% and 26% reductions, respectively, in emergency department (ED) visits ($P < 0.0001$)

An Increase in Viral Load Increases the per-Act Risk of Transmission by 2.9-Fold

CI = confidence interval.
Figure adapted from Hughes et al. J Infect Dis. 2012;205:358-65.
Switching

- Switching among commercially insured and Medicaid HIV patients results in higher nonpharmacy and total costs versus nonswitchers.
- Switching early (≤ 90 days) results in higher nonpharmacy and total costs versus nonswitchers in both commercially insured and Medicaid HIV patients.
- Switching results in higher nonpharmacy and total costs versus nonswitchers.
  - Third-agent switching: costs per person-year were significantly higher in second- and third-line treatment as compared with first-line treatment.
Summary

- HIV leads to substantial disease burden
- Adherence is key to treatment success
  – Poor adherence may lead to resistance and greater economic burden
- Currently available antiretrovirals may be suboptimal, leading to efficacy/safety trade-offs
- ART has transformed HIV into a chronic disease, but it has a substantial cost and is associated with new burdens and costs such as HAART–related AEs, virologic failure, and viral resistance

AE = adverse event; HAART = highly active antiretroviral therapy.
Product Value

Market Access Overview

Key Issues in the US Health Care Market

- The Patient Protection and Affordable Care Act is designed to expand health coverage to 32 million uninsured Americans by 2019; the act makes significant changes to public and private health insurance systems that will affect providers of HIV care\(^a\)

- Access to antiretrovirals through Medicare and Medicaid is worsening, and deficiencies in AIDS Drug Assistance Programs (ADAPs) are increasing\(^b\)

- The Patient Protection and Affordable Care Act also phases out the Medicare Part D prescription drug benefit “donut hole,” giving Medicare enrollees living with HIV and AIDS the peace of mind that they will be better able to afford their medications\(^c\)

---

## Competitor Overview

Currently Available Drugs May Be Suboptimal, Leading to Efficacy/Safety Tradeoffs

<table>
<thead>
<tr>
<th>Key Limitations</th>
<th>Drug 1</th>
<th>Drug 2</th>
<th>Drug 3</th>
<th>Drug 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Limitation 1</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>Limitation 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Limitation 3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Limitation 4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Limitation 5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Limitation 6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Limitation 7</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Limitation 8</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Header

- Text

### Key Objectives

<table>
<thead>
<tr>
<th>Disease Problem and Unmet Need</th>
<th>Product Value</th>
<th>Product X Payer Value Proposition</th>
</tr>
</thead>
</table>

---

**The power of knowledge.**

**The value of understanding.**
### Key Objectives

- Text